Phio Pharmaceuticals Corp.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
PHIO$0.84+4.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ITEM 6. | EXHIBITS |
|---|
EXHIBIT INDEX
| Exhibit Number | Description | Date |
| 3.1 | Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. | November 19, 2018 |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. | January 14, 2020 |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. | January 25, 2023 |
| 3.4 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. | July 2, 2024 |
| 3.5 | Certificate of Designation of Series D Preferred Stock, dated November 16, 2022. | November 16, 2022 |
| 3.6 | Amended and Restated Bylaws of Phio Pharmaceuticals Corp. | May 2, 2022 |
| 4.1 | Form of Warrant. | September 28, 2018 |
| 4.2 | Form of Warrant. | April 2, 2020 |
| 4.3 | Form of Common Stock Warrant. | January 25, 2021 |
| 4.4 | Form of Placement Agent Warrant. | February 17, 2021 |
| 4.5 | Form of Placement Agent Warrant. | December 8, 2023 |
| 4.6 | Form of Series C/D Warrant. | July 12, 2024 |
| 4.7 | Form of Placement Agent Warrant. | July 12, 2024 |
| 4.8 | Form of Placement Agent Warrant. | December 20, 2024 |
| 4.9 | Form of Placement Agent Warrant. | December 26, 2024 |
| 4.10 | Form of Placement Agent Warrant. | January 14, 2025 |
| 4.11 | Form of Placement Agent Warrant. | January 15, 2025 |
| 4.12 | Form of Placement Agent Warrant. | January 17, 2025 |
| 4.13 | Form of Series J/K Warrant | July 30, 2025 |
| 4.14 | Form of Placement Agent Warrant | July 30, 2025 |
| 4.15 | Form of Series A Warrant | November 6, 2025 |
| 4.16 | Form of Placement Agent Warrant* | |
| 10.1# | Form of Inducement Letter Agreement dated November 3, 2025, by and between Phio Pharmaceuticals Corp. and the Holders* | |
| 10.2# | Separation Agreement and General Release of Claims, dated August 11, 2025, by and between the Company and Robert Infarinato. | August 14, 2025 |
| 31.1 | Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer.* | |
| 31.2 | Sarbanes-Oxley Act Section 302 Certification of Principal Financial Officer.* | |
| 32.1 | Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer and Principal Financial Officer.** | |
| 101.INS | Inline XBRL Instance Document.* | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document.* | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document.* | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document.* | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document.* | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document.* | |
| 104 | The cover page for this report, formatted in Inline XBRL (included in Exhibit 101).* |
| * | Filed herewith. |
|---|---|
| ** | Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act. |
| # | Indicates a management contract or compensatory plan or arrangement. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.